In contrast, The United States submits that Geelong's claim under Article 2.1 of the TBT Agreement is based on a flawed analysis and insufficient evidence. The United States contends that the national treatment obligation contained in Article 2.1 is "not intended to prevent legitimate measures, such as section 907 (a) (1) (A), that establish neutral product standards based on public health criteria".
đang được dịch, vui lòng đợi..